PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with LifeSci Acquisition 2 Corp in February 2022, a blank-check vehicle sponsored by LifeSci Acquisition 2 LLC, an affiliate of LifeSci Capital. The SPAC priced its IPO in 2021, targeting the life sciences and biotechnology sector. Pardes focused on developing oral antiviral therapies, including a protease inhibitor candidate directed at COVID-19 and other viral infections. Following a strategic review, the company announced a wind-down of operations in early 2023 and submitted an 8-K to the SEC on August 31, 2023, reflecting corporate activity during that dissolution period. Sign up at SpacDesk for complete filing histories, deal analytics, and SPAC transaction data across the full market.